Vanguard Capital Management’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$29.1M Sell
4,887,083
-52,514
-1% -$249K ﹤0.01% 2196
2026
Q2
$21.9M Buy
4,939,597
+176,693
+4% +$754K ﹤0.01% 2400
2026
Q1
$20.8M Buy
+4,762,904
New +$22.5M ﹤0.01% 2320

Other funds holding CTKB

Vanguard Capital Management's CTKB Position: Q3 2026 in Review

Vanguard Capital Management reduced its Cytek Biosciences (CTKB) stake by 1.1% in Q3 2026, selling an estimated $249K and leaving 4,887,083 shares worth $29.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

Vanguard Capital Management first reported a position in CTKB in Q1 2026 and has held it in 3 quarters since. 152 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Vanguard Capital Management held 4,887,083 shares of Cytek Biosciences worth $29.1M as of Q3 2026.
  • Vanguard Capital Management sold 52,514 Cytek Biosciences shares in Q3 2026, an estimated $249K.
  • Cytek Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2196 holding.
  • Vanguard Capital Management first reported a position in Cytek Biosciences in Q1 2026 and has held it in 3 quarters since.
  • 152 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.